Total
0
Shares
Clinuvel Pharmaceuticals (ASX:CUV) - Chief Executive Officer, Philippe Wolgen
Chief Executive Officer, Philippe Wolgen
Source: The Photoprotection Channel
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Clinuvel Pharmaceutical’s (CUV) marked its decade of consecutive half-year profits with a 962 per cent leap in after-tax profits over its most recent six-month period
  • The biopharmaceutical reported a net profit of $6.4 million and revenue of $15.6 million, representing a 58 per cent spike on the prior corresponding period
  • The company attributed the growth predominantly to the distribution of its SCENSSE treatment, which prevents prevent phototoxicity in adult patients with erythropoietic protoporphyria (EPP)
  • Expenditure was up 5 per cent over the interval as the company upped its research and development programme
  • Clinuvel’s Chief Financial Officer said the company’s long term strategy and focus had been reaffirmed by the half-yearly results
  • Clinuvel closed the day down a slight 1.20 per cent, trading at $19.80 per share

Clinuvel Pharmaceutical’s (CUV) marked its decade of consecutive half-year profits with a 962 per cent leap in after-tax profits over its most recent six-month period.

For the half year ended December 31, the biopharmaceutical reported a net profit of $6.4 million and revenue of $15.7 million, a 58 per cent increase on the prior corresponding period.

The jump in revenue was predominantly driven by the distribution of its SCENSSE drug, which is administered to prevent phototoxicity in adult patients with erythropoietic protoporphyria (EPP).

Clinuvel has also flagged plans to work towards gaining regulatory approval for SCENSSE in EPP patients in other markets worldwide.

The company said it had managed to deliver the impressive figures despite the economic downturn, pursuing operations in the European economic area and making progress in its commercial operations in the U.S.

CUV also managed to bolster its balance sheet, increasing its cash reserves by 9 per cent.

Expenditure was up 5 per cent for the interval, with the company allocating increased investment in its research and development programme.

Clinuvel’s Chief Financial Officer Darren Keamy said the company’s long term strategy and focus had been reaffirmed by the half-yearly results.

“Despite ongoing global economic uncertainty, our team has expanded distribution for our leading drug SCNESSE in both the U.S. and Europe,” he explained.

“We are investing in our research and development and clinical programmes and progressing our evolution into a diversified pharmaceutical company,” he concluded.

Clinuvel closed the day down a slight 1.20 per cent, trading at $19.80 per share.

CUV by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.